Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Prediction: 3 Stocks That'll Be Worth More Than Berkshire Hathaway 5 Years From Now
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
Why Eli Lilly Stock Topped the Market Today
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
Investor's Business Daily on MSN20h
Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms
Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.
MM&M21h
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...